HIMs 22% Collapse Looks Like A ‘Buy The Dip’ Moment

Shares of Hims & Hers Health (NYSE:HIMS) plunged 22% at market open on Monday, February 9. The telehealth company pulled its copycat semaglutide weight-loss pill over the weekend after threats of legal action from Novo Nordisk (NYSE:NVO | NVO Price Prediction) and the FDA. Reddit traders responded with increased discussion, with sentiment scores reaching 88 (very bullish).

The stock has been under severe pressure, falling 43% over the past year and 35% in the past month alone. Technical indicators confirm oversold conditions, with RSI collapsing to 23.71, well below the 30 threshold that typically signals a potential reversal.

Reddit Traders Discuss Regulatory Pressure

Activity on r/WallStreetBets surged dramatically as the stock fell. The most engaged post, “Hims & Hers to stop offering copies of Novo Nordisk’s new Wegovy pill,” drew 1,596 upvotes and 174 comments.

Hims & Hers to stop offering copies of Novo Nordisk’s new Wegovy pill
by
a user in
wallstreetbets

Another post titled “$HIMS YOLO” attracted 389 upvotes and 256 comments, with traders sharing positions despite the regulatory setback.

$HIMS YOLO
by
a user in
wallstreetbets

The company’s fundamentals remain solid beneath the regulatory noise:

• Revenue surged 49% year-over-year to $599 million in Q3 2025, beating estimates
• Subscriber base grew 21% to 2.5 million users
• Adjusted EBITDA jumped 53% to $78.4 million

Peer Context and What’s Next for Hims

The regulatory pressure specifically targets compounded GLP-1 drugs, creating a potential competitive moat if Novo Nordisk succeeds in eliminating copycat products. Hims had positioned its $49 oral semaglutide as a cheaper alternative to Wegovy’s $150 price point, but the company’s core telehealth platform remains intact. With sentiment rebounding to 70 on a 100-point scale and RSI at oversold levels, retail traders are discussing the stock’s technical position.

Contact [email protected] for any questions or corrections.